NAFDAC boosts Nigeria local drug manufacturing
Analysis based on 8 articles · First reported Sep 06, 2026 · Last updated Sep 07, 2026
The policy shift is expected to boost Nigeria's domestic pharmaceutical manufacturing sector, attracting investment and reducing import dependence. This could improve the country's trade balance and strengthen the local industry, though it may increase costs for import-dependent firms in the short term.
NAFDAC's 5+5 Policy and Ceiling List initiatives, introduced in 2019 and expanded since, have significantly reshaped Nigeria's pharmaceutical industry by restricting imports of medicines that can be produced locally. According to NAFDAC Director-General Mojisola Adeyeye, speaking at the Lagos Chamber of Commerce and Industry's Invest in Nigeria Conference and Expo 4.0, these measures have cut imports of affected drug products by 70% and increased local manufacturing by 25%. The number of pharmaceutical manufacturing companies rose from 174 to 190, and the import-to-local production ratio improved from 70:30 in 2019 to 50:50 in 2025. Contract manufacturing expanded from 10 companies in 2019 to 87 in 2026. As of June 2026, NAFDAC had approved facility layouts for 176 pharmaceutical companies, including 106 new entrants. The agency also reported 28 newly developed or retrofitted companies and 16 new facilities, totaling 44. These developments are supported by President Bola Tinubu's 2024 Executive Order providing zero tariffs, excise duties, and VAT on imported machinery and raw materials for local healthcare manufacturing. NAFDAC is extending similar local manufacturing strategies to food and cosmetics sectors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard